Synthesis and in vitro antiproliferative activity of novel androst-5-ene triazolyl and tetrazolyl derivatives

Article abstract of DOI:10.3390/molecules16064786

A straightforward and reliable method for the regioselective synthesis of steroidal 1,4-disubstituted triazoles and 1,5-disubstituted tetrazoles via copper(I)-catalyzed cycloadditions is reported. Heterocycle moieties were efficiently introduced onto the starting azide compound 3β-acetoxy- 16β-azidomethylandrost-5-en-17β-ol through use of the "click" chemistry approach. The antiproliferative activities of the newly-synthesized triazoles were determined in vitro on three human gynecological cell lines (HeLa, MCF7 and A2780) using the microculture tetrazolium assay.

Full text of DOI:10.3390/molecules16064786

Molecules 2011, 16, 4786-4806; doi:10.3390/molecules16064786
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis and In Vitro Antiproliferative Activity of Novel
Androst-5-ene Triazolyl and Tetrazolyl Derivatives
Zalán Kádár 1,*, Dóra Kovács 1, Éva Frank 1, Gyula Schneider 1, Judit Huber 2, István Zupkó 2,
Tibor Bartók 3,4 and János Wölfling 1,*
1
Department of Organic Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary
2
Department of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6,
H-6720 Szeged, Hungary
3
Faculty of Engineering, University of Szeged, Moszkvai krt. 5-7, H-6725 Szeged, Hungary
4
Fumizol Ltd., Moszkvai krt. 5-7, H-6725 Szeged, Hungary
* Authors to whom correspondence should be addressed; E-Mails: wolfling@chem.u-szeged.hu (J.W.);
zkadar@chem.u-szeged.hu (Z.K.); Tel.: +36-62-544-200; Fax: +36-62-544-200.
Received: 12 May 2011; in revised form: 2 June 2011 / Accepted: 6 June 2011 /
Published: 9 June 2011
Abstract: A straightforward and reliable method for the regioselective synthesis of
steroidal 1,4-disubstituted triazoles and 1,5-disubstituted tetrazoles via copper(I)-catalyzed
cycloadditions is reported. Heterocycle moieties were efficiently introduced onto the
starting azide compound 3β-acetoxy-16β-azidomethylandrost-5-en-17β-ol through use of
the “click” chemistry approach. The antiproliferative activities of the newly-synthesized
triazoles were determined in vitro on three human gynecological cell lines (HeLa, MCF7
and A2780) using the microculture tetrazolium assay.
Keywords: click chemistry; steroid azides; triazoles; tetrazoles; CuAAC
1. Introduction
In the past few years, the Huisgen 1,3-dipolar cycloaddition of azides and terminal alkynes to form
triazoles has received revived attention. Since the independent reports of Sharpless [1] and Meldal [2],
this process has become the most extensively studied “click” reaction, as evidenced by a nearly
exponential growth in the number of related publications. Compared with the non-catalyzed version

Molecules 2011, 16
4787
the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) has certain advantageous properties,
such as regioselectivity, versatility, high conversions and the lack of by-products [3-5]. Moreover, this
process performs well in most common laboratory solvents and usually does not require protection
from oxygen and water, making it an ideal tool for the synthesis of libraries for initial screening and
structure-activity profiling.
In contrast, other 1,3-dipolar cycloadditions between nitriles and organic azides to afford tetrazoles
generally requires highly electrophilic nitrile carbon atoms and harsh conditions [6]. Demko and
Sharpless recently reported the syntheses of some 1,5-disubstituted tetrazoles [7,8] under solvent-free
conditions at 100-120 °C. Furthermore, a series of potential catalysts for these reactions were
investigated by Vilarrasa et al. [9], with the aim of achieving milder conditions. The commercially
available or easily prepared [10] copper(I) triflate was observed to be the most efficient catalyst.
To the best of our knowledge, only a few examples are to be found in the literature in which
1,3-dipolar cycloadditions have been applied to steroidal azides [11-15]. Thus, in continuation of our
program on the synthesis of steroidal heterocycles [16-19], we set out to develop an effective route for
the production of novel steroidal triazoles and tetrazoles through use of the “click” chemistry
approach. The present paper reports the syntheses of D-ring-substituted androst-5-ene derivatives
containing a 1,4-disubstituted triazole (compounds 6a-j, 7a-j) or a 1,5-disubstituted tetrazole moieties
(compounds 9a-e, 11a-e).
Five-membered nitrogen heterocycles play an important role in biological systems. Not
surprisingly, a number of compounds containing 1,2,3-triazoles are found to exhibit a broad spectrum
of biological activities, including antimicrobial [20], anti-HIV [21], antiallergic [22] and antiviral [23]
effects. A set of 1,2,3-triazol-1-yl podophyllotoxin derivatives were synthesized and some of them
proved to be more potent in inhibiting the growth of human cancer cells than etoposide [24]. Several
benzotriazoles proved to be novel and potent antiproliferative agents and some of them exhibited
nanomolar IC50 values against human adherent cancer cell lines [25]. A series of substituted tetrazol-5-
ones have been synthesized and three of them were found to inhibit leukemia and breast cancer growth
in vitro [26]. On the basis of these reports, the triazole and tetrazole ring systems can therefore be
regarded as structural blocks suitable for improvement of the anticancer properties of potential
pharmacons. Since we reported a set of androstene-fused arylpyrazolines as antiproliferative
compounds, it appeared rational to improve the pharmacological profile of the skeleton by means of
the introduction of a triazole or tetrazole moiety [19]. Moreover, some 21-triazolyl derivatives of
pregnenolone were recently reported as potential anticancer agents by Banday et al. [15]. Thus, the
newly-prepared triazolyl derivatives were screened in vitro for their activities against a panel of three
human malignant cell lines.
2. Results and Discussion
2.1. Synthesis
To prepare novel steroid triazoles via 1,3-dipolar cycloaddition, 3β-acetoxy-16β-azidomethylandrost-
5-en-17β-ol (5) was chosen as starting compound. The synthetic strategy for the preparation of the
starting azide is illustrated in Scheme 1.

Molecules 2011, 16
4788
Scheme 1. Synthesis of the steroid azide.
O
O
OH
OR
OH
H
H
H
b
H
H
H
H
H
H
HO
RO
a
AcO
2a R=H
1
3a-c
2b R=Ac
OH
OH
OH
OH
H
N3
OTs
c
d
H
H
H
H
AcO
4
5
3a
Reagents and conditions: (a) Ac2O, pyridine; (b) KBH4, MeOH/EtOH (1:1); (c) TsCl, pyridine;
(d) NaN3, DMF, 70 °C, 6 h.
The reaction of 3β-hydroxy-16-hydroxymethylideneandrost-5-en-17-one (2a) [27] with acetic
anhydride in pyridine medium afforded the diacetate 2b in excellent yield. According to our earlier
observation [28], the reduction of 3β-acetoxy-16-acetoxymethylideneandrost-5-en-17-one (2b) with
KBH4 under pH-controlled conditions leads to three diol isomers. Two of them (compounds 3a, 3b),
containing 17β-hydroxy groups with opposite configurations at C-16, were isolated in nearly identical
amounts, while the third one, the 16β,17α isomer 3c, was obtained in a significantly smaller quantity
(~5%). After separation of the 16β,17β-hydroxymethyl isomer 3a by flash chromatography, the
primary hydroxy group in 3a was converted into a good leaving group with p-toluenesulfonyl chloride.
Finally, the crude product 4 was used without purification for further nucleophilic substitution
with NaN3 in DMF to provide the desired 3β-acetoxy-16β-azidomethylandrost-5-en-17β-ol (5) in
good yield.
Several D-ring-substituted androst-5-ene derivatives containing a 1,2,3-triazole ring (compounds
6a-j) were synthesized by the reaction of 5 with various terminal alkynes through use of the “click”
chemistry approach (Table 1). Although there are a number of methods for generation of the active
catalyst [29], one of the most common techniques was chosen. Thus, the Cu(I) species was generated
in situ by the reduction of CuSO4·5H2O with sodium ascorbate to minimize the formation of
by-products. Furthermore, a mixture of CH2Cl2 as solvent and water as co-solvent was employed to
eliminate the need for ligands and to simplify the reaction protocol [30].
In all cases, total consumption of the starting compound was observed within 1-4 h at room
temperature. The reactions were very selective, and triazole products could be isolated in 78-93%
yields. The trace quantities of copper and reagents remaining in the reaction mixtures were removed by
flash chromatography. Treatment of 6a-j containing a 3β-acetyl group with KOH in MeOH at 50 °C
resulted in the corresponding 3β-hydroxy compounds 7a-j in good yields (Table 1).

Molecules 2011, 16
Table 1. Synthesis of the 1,4-disubstituted steroidal triazoles and hydrolysis of their 3-acetyl groups.
4789
OH
OH
N
N
N
N3
CuSO4·5H2O (5 mol%)
NaAsc (15 mol%)
H
H
R1
+
R1
H
H
H
H
CH2Cl2/H2O (1:1), r.t.
RO
AcO
5
6a-j R=Ac
7a-j R=H
KOH
MeOH
Triazoles
Entry
R1
Yield a (%) of 6
Yield a (%) of 7
(6 and 7)
1
2
a
89
91
82
81
b
c
3
4
5
91
93
86
88
85
86
d
e
6
7
8
f
83
85
90
87
91
82
g
h
9
i
87
78
90
83
10
j
a Yields of purified isolated products.
These outstanding results encouraged us to investigate another example of “click” reactions. The
intermolecular [3+2] cycloadditions between the steroid azides 5 and 10 and several nitriles 8a-e
containing an electron-withdrawing group (EWG) afforded the desired 1,5-disubstituted steroidal
tetrazoles 9a-e and 11a-e. As mentioned earlier, highly electrophilic nitrile carbon atoms are required
for successful addition [9]; some commercially available acyl cyanides and cyanoformates were
therefore chosen as reagents. In all cases, the reactions were carried out at room temperature, with
stirring for 2 days, 10 mol % copper(I) complex Cu2(OTf)2·C6H6 (OTf = O3SCF3) being used as
catalyst. The newly-synthesized tetrazolyl compounds could be isolated in 45-72% yields after
purification by column chromatography (Table 2).

Molecules 2011, 16
4790
Table 2. Synthesis of the 1,5-disubstituted steroidal tetrazoles.
OH
OH
N
N3
N
N
Cu2(OTf)2·C6H6
H
H
(10 mol%)
N
+
EWG
N
H
H
H
H
EWG
CH2Cl2, r.t.
RO
RO
8a-e
5
R=Ac
9a-e R=Ac
11a-e R=H
KOH
MeOH
10 R=H
Entry
Reactant
EWG
Yield a (%) of 9a-e
Yield a (%) of 11a-e
1
8a
8b
8c
8d
8e
66
59
MeOCO
EtOCO
BnOCO
MeCO
PhCO
2
3
4
5
72
62
57
54
64
53
47
45
a Yields of purified isolated products.
1
13
The structures of all synthesized compounds were confirmed by H- and in some cases, C-NMR
measurements. The 1H-NMR spectra of 6a-i and 7a-i revealed the appearance of the new signals of the
incorporated aryl groups at 6.9-8.5 ppm as compared with the spectra of the starting azide 5, while the
5’-H singlet of the newly-formed heterocycle was identified at 7.8-8.5 ppm. Compounds 6j and 7j
containing a cycloalkyl substituent were exceptions, with a chemical shift of 7.28 ppm (5’-H). As far
as the tetrazolyl derivatives are concerned, the newly-formed heterocycle does not contain any protons,
but the signal of 5’-C can be identified at 145-149 ppm in the corresponding 13C-NMR spectra.
Furthermore, in the cases of 9c, 11c and 9e, 11e the new signals of the incorporated Ph ring appeared
at 7.3-8.3 ppm in the 1H-NMR spectra.
2.2. Biological Activity
Compounds 7a-j and 11a-e were screened for anticancer activity against a panel of three human
cancer cell lines (Table 3). Although there is no generally accepted threshold for efficacy, when the
inhibition of cell growth is less than 25% at 30 µM, such a substance may be considered ineffective.
No clear structure-activity relationships could be concluded, but triazole-containing androst-5-enes
exhibit substantial antiproliferative activity, for which a substituted aromatic group of the triazole ring
is preferred. The antiproliferative action of a compound with an unsubstituted phenyl group on the
triazole ring (compound 7a) could be maintained or moderately increased by substitution in the
para or meta position (compounds 7b-e, 7g), while ortho-OMe (compound 7f) was less effective.
Nevertheless, an amino group in the meta position offers no advantage (compound 7h). A pyridyl, but
not a cyclopropyl group, instead of phenyl (compounds 7i-j) could be beneficial. Although inactive on
HeLa cells at 10 µM, 7c is considered the most effective of the presented compounds. In contrast,
tetrazoles substituted on the D-ring of the steroidal skeleton proved to be ineffective with the exception
of 11e, which has a moderate effect.

Molecules 2011, 16
4791
Table 3. Antiproliferative effects of the synthesized compounds.
Growth inhibition % (±SEM)
Product
µM
10
30
10
30
10
30
10
30
10
30
10
30
10
30
10
30
10
30
10
30
10
30
10
30
10
30
HeLa
MCF7
A2780
64.6 (±1.6)
72.6 (±1.9)
77.6 (±0.7)
79.2 (±0.7)
<25
35.7 (±0.8)
37.2 (±2.2)
40.8 (±1.8)
54.8 (±2.6)
41.6 (±0.2)
83.7 (±1.3)
47.0 (±2.1)
47.6 (±1.6)
60.2 (±1.9)
62.6 (±0.7)
<25
<25 *
7a
7b
26.9 (±2.7)
35.7 (±2.2)
36.8 (±1.6)
54.1 (±2.6)
88.5 (±2.1)
45.0 (±2.9)
46.8 (±0.9)
30.9 (±2.2)
32.8 (±1.4)
42.3 (±2.7)
47.8 (±2.1)
31.4 (±2.6)
45.6 (±2.4)
42.1 (±1.2)
53.2 (±0.9)
31.1 (±1.9)
43.3 (±2.1)
42.3 (±2.6)
47.5 (±1.4)
<25
7c
96.9 (±1.7)
78.1 (±0.6)
78.6 (±1.4)
68.7 (±0.3)
74.4 (±0.7)
<25
7d
7e
7f
<25
27.1 (±1.3)
54.5 (±1.1)
59.3 (±1.8)
<25
61.8 (±0.3)
68.4 (±0.3)
49.2 (±1.3)
66.2 (±0.8)
55.7 (±2.6)
93.2 (±0.8)
61.7 (±0.4)
63.6 (±0.7)
<25
7g
7h
28.6 (±2.4)
46.5 (±2.1)
63.8 (±1.0)
31.3 (±1.1)
50.5 (±1.1)
<25
7i
7j
11a-d
11e
Cisplatin
<25
<25
<25
<25
<25
<25
<25
61.8 (±1.7)
88.6 (±0.5)
90.2 (±1.8)
72.0 (±0.4)
53.0 (±2.3)
86.9 (±1.2)
42.6 (±2.3)
99.9 (±0.3)
* Compounds eliciting less than 25% inhibition of proliferation were considered ineffective, and for
simplicity the exact results are not given.

Molecules 2011, 16
4792
3. Experimental
3.1. General
Melting points (mp) were determined on a Kofler block and are uncorrected. The reactions were
monitored by TLC on Kieselgel-G (Merck Si 254 F) layers (0.25 mm thick); solvent systems (ss): (A)
CH2Cl2/EtOAc (95:5 v/v), (B) CH2Cl2/EtOAc (80:20 v/v), (C) CH2Cl2/EtOAc (50:50 v/v). The spots
were detected by spraying with 5% phosphomolybdic acid in 50% aqueous phosphoric acid. The
Rf values were determined for the spots observed by illumination at 254 and 365 nm. Flash
chromatography: Merck silica gel 60, 40-63 μm. All solvents were distilled prior to use. Reagents and
materials were obtained from commercial suppliers and were used without purification.
Elementary analysis data were determined with a PerkinElmer CHN analyzer model 2400 and IR
spectra were recorded on a BioRad FTS 60A FTIR spectrometer. NMR spectra were obtained at room
temperature with a Bruker DRX 500 instrument. Chemical shifts are reported in ppm (δ scale), and
coupling constants (J) in Hz. For the determination of multiplicities, the J-MOD pulse sequence was used.
Automated flow injection analyses were performed by using an HPLC/MSD system. The system
comprised an Agilent 1100 micro vacuum degasser, a quaternary pump, a micro-well plate autoinjector
and a 1946A MSD equipped with an electrospray ion source (ESI) operated in positive ion mode. The
ESI parameters were: nebulizing gas N2, at 35 psi; drying gas N2, at 350 °C and 12 L/min; capillary
voltage (VCap) 3000 V; fragmentor voltage 70 V. The MSD was operated in scan mode with a mass
range of m/z 60−620. Samples (0.2 μL) with automated needle wash were injected directly into the
solvent flow (0.3 mL/min) of CH3CN/H2O, 70:30 (v/v) supplemented with 0.1% formic acid. The
system was controlled by Agilent LC/MSD Chemstation software.
3.2. 3β-Acetoxy-16-acetoxymethylideneandrost-5-en-17-one (2b)
Compound 2a (19.9 g, 63 mmol) was dissolved in a mixture of pyridine (40 mL) and Ac2O
(40 mL), and the solution was stirred overnight, and then poured onto a mixture of ice and H2SO4
(18 mL). The precipitate was collected by filtration, washed to neutrality and dried, resulting in 23.8 g
(94%) of 2b, mp 199-202 °C (lit. [28] mp 198-200 °C), Rf = 0.68 (ss A).
3.3. 3β-Acetoxy-16β-hydroxymethylandrost-5-en-17β-ol (3a)
Finely powdered 2b (23.8 g, 59.5 mmol) was suspended in a mixture of MeOH and EtOH (1:1, 500
mL), and KBH4 (8 g, 148 mmol) was added in small portions. To maintain pH 6-8, the solution was
repeatedly acidified as needed with MeOH/AcOH (1:1), using bromothymol blue as indicator. After
completion of the reaction, the mixture was diluted with water and acidified with dilute HCl. The
precipitate that formed was filtered off and washed with water to neutrality. The resulting crude
product was purified by column chromatography, with CH2Cl2/EtOAc (8:2) as eluent, yielding 3a
as a white solid (10.35 g, 48%), mp 197-199 °C (lit. [28] mp 199-201 °C), Rf = 0.44 (ss C). The
spectroscopic data were consistent with those reported in the literature.

Molecules 2011, 16
4793
3.4. 3β-Acetoxy-16β-p-toluenesulfonyloxymethylandrost-5-en-17β-ol (4)
Compound 3a (7.25 g, 20 mmol) was dissolved in pyridine (50 mL), and a solution of p-toluene-
sulfonyl chloride (7 g, 35 mmol) in pyridine (10 mL) was then added dropwise while cooling in ice.
The reaction mixture was allowed to stand overnight, and was then poured into a mixture of ice and
H2SO4 (20 mL). The precipitate that formed was filtered off and washed with water to neutrality. This
substance was used in the subsequent step without further purification and characterization.
3.5. 3β-Acetoxy-16β-azidomethylandrost-5-en-17β-ol (5)
Sodium azide (1.8 g, 28 mmol) was added to a solution of 4 (5.8 g, 11 mmol) in DMF (80 mL). The
reaction mixture was stirred at 70 °C for 6 h and was then poured into water. The precipitate that
formed was allowed to stand overnight, and then filtered off and washed with water. Purification of the
resulting crude product by column chromatography with CH2Cl2 as eluent afforded 5 as a white solid
(3.75 g, 86%), mp 144-145 °C, Rf = 0.58 (ss A); 1H-NMR (CDCl3); δ [ppm] = 0.78 (s, 3H, 18-CH3),
0.95 (m, 1H), 1.03 (s, 3H, 19-CH3), 1.08-1.17 (overlapping m, 3H), 1.45 (m, 1H), 1.51-1.62
(overlapping m, 5H), 1.82-1.90 (overlapping m, 4H), 1.99 (m, 1H), 2.03 (s, 3H, Ac-CH3), 2.32 (m, 2H,
4-H2), 2.38 (m, 1H, 16-H), 3.31 (dd, 1H, J = 12.0 Hz, J = 6.5 Hz, 16a-H), 3.57 (dd, 1H, J = 12.0 Hz,
J = 7.0 Hz, 16a-H), 3.79 (d, 1H, J = 10.0 Hz, 17-H), 4.60 (m, 1H, 3-H), 5.37 (d, 1H, J = 5.0 Hz, 6-H);
13C-NMR (CDCl3); δ [ppm] = 12.1 (C-18), 19.3 (C-19), 20.5 (C-11), 21.4 (Ac-CH3), 27.7, 30.5, 31.1,
31.6, 36.6, 37.0, 37.4, 38.0, 39.9, 43.6, 49.9, 50.0, 53.3, 73.8 (C-3), 81.3 (C-17), 122.1 (C-6), 139.7
(C-5), 170.5 (Ac-CO); IR (neat, cm−1) 3526, 2945, 2909, 2112, 1717, 1439, 1365, 1256, 1032.
ESI-MS: 388 (M+H)+; Anal. Calcd for C22H33N3O3 C, 68.19; H, 8.58; N, 10.84. Found: C, 68.01; H,
8.73; N, 11.04.
3.6. General Procedure for Preparation of 3β-acetoxy-16β-(4-phenyl-, substituted 4-phenyl- or
4-cycloalkyl-1H-1,2,3-triazol-1-ylmethyl)androst-5-en-17β-ols 6a-j
Compound 5 (387 mg, 1 mmol) was dissolved in CH2Cl2 (10 mL), and a solution of CuSO4·5H2O
(12.5 mg, 5 mol %) and sodium ascorbate (30 mg, 15 mol %) in water (10 mL) was poured into the
organic phase. The appropriate terminal alkyne (1.1 mmol) was added to the reaction mixture, which
was then stirred for 1-4 h at ambient temperature. After the disappearance of the starting material (TLC
monitoring), the two-phase solution was diluted with water (20 mL) and extracted with CH2Cl2
(2 × 20 mL). The combined organic layers were washed with water, dried over Na2SO4 and evaporated
in vacuo. The resulting crude product was purified by flash chromatography with CH2Cl2/EtOAc
(90:10), or CH2Cl2/EtOAc (80:20) as eluent.
3β-Acetoxy-16β-(4-phenyl-1H-1,2,3-triazol-1-ylmethyl)androst-5-en-17β-ol (6a): Alkyne: phenyl-
acetylene (0.12 mL). After purification, 6a was obtained as a white solid (435 mg, 89%), mp
1
251-252 °C, Rf = 0.30 (ss B); H-NMR (CDCl3); δ [ppm] = 0.80 (s, 3H, 18-CH3), 0.89 (m, 1H), 1.02
(s, 3H, 19-CH3), 1.11-1.20 (overlapping m, 3H), 1.37-1.59 (overlapping m, 6H), 1.80-1.91
(overlapping m, 4H), 1.97 (dd, 1H, J = 12.0 Hz, J = 2.5 Hz), 2.03 (s, 3H, Ac-CH3), 2.32 (m, 2H, 4-H2),

Molecules 2011, 16
4794
2.74 (m, 1H, 16-H), 3.88 (d, 1H, J = 10.0 Hz, 17-H), 4.32 (dd, 1H, J = 13.5 Hz, J = 6.5 Hz, 16a-H),
4.58 (m, 1H, 3-H), 4.70 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.34 (br s, 1H, 6-H), 7.32 (t, 1H, J = 7.0
Hz, 4”-H), 7.41 (t, 2H, J = 7.0 Hz, 3”- and 5”-H), 7.82 (m, 3H, 2”-, 6”- and 5’-H); 13C-NMR (CDCl3);
δ [ppm] = 12.3 (C-18), 19.3 (C-19), 20.5 (C-11), 21.4 (Ac-CH3), 27.7, 31.0, 31.1, 31.6, 36.6, 37.0,
37.3, 38.0, 41.3, 43.7, 49.9, 50.0, 52.0, 73.8 (C-3), 80.6 (C-17), 120.6 (C-5’), 122.0 (C-6), 125.7 (2C,
C-2” and C-6”), 128.2 (C-4”), 128.8 (2C, C-3” and C-5”), 130.2 (C-1”), 139.7 (C-5), 147.2 (C-4’),
170.6 (Ac-CO); IR (neat, cm−1) 3404, 2941, 2910, 1732, 1373, 1242, 1034, 772, 706. ESI-MS: 490
(M+H)+; Anal. Calcd for C30H39N3O3: C, 73.59; H, 8.03; N, 8.58. Found: C, 73.70; H, 8.19; N, 8.76.
3β-Acetoxy-16β-[4-(4-ethylphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6b): Alkyne:
4-ethylphenylacetylene (0.15 mL). After purification, 6b was obtained as a white solid (470 mg, 91%),
1
mp 249-250 °C, Rf = 0.36 (ss B); H-NMR (CDCl3); δ [ppm] = 0.79 (s, 3H, 18-CH3), 0.94 (m, 1H),
1.02 (s, 3H, 19-CH3), 1.09-1.21 (overlapping m, 3H), 1.25 (t, 3H, J = 7.5 Hz, Et-CH3), 1.41-1.62
(overlapping m, 6H), 1.79-1.92 (overlapping m, 4H), 1.95 (dd, 1H, J = 12.5 Hz, J = 2.5 Hz), 2.03 (s,
3H, Ac-CH3), 2.32 (m, 2H, 4-H2), 2.67 (q, 2H, J = 7.5 Hz, Et-CH2), 2.73 (m, 1H, 16-H), 3.87 (d, 1H,
J = 10.0 Hz, 17-H), 4.30 (dd, 1H, J = 13.5 Hz, J = 6.5 Hz, 16a-H), 4.58 (m, 1H, 3-H), 4.69 (dd, 1H,
J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.34 (br s, 1H, 6-H), 7.24 (d, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.72
(d, 2H, J = 7.5 Hz, 2”- and 6”-H), 7.79 (s, 1H, 5’-H); 13C-NMR (CDCl3); δ [ppm] = 12.3 (C-18), 19.3
(C-19), 20.5 (C-11), 21.4 (Ac-CH3), 27.7, 28.6, 31.0, 31.1, 31.6, 36.6, 36.9, 37.0, 37.3, 38.0, 41.3,
43.7, 49.9, 50.0, 52.0, 73.8, 80.6, 120.3 (C-5’), 122.1 (C-6), 125.7 (2C, C-2” and C-6”), 127.7 (C-1”),
128.3 (2C, C-3” and C-5”), 139.7 (C-5), 144.4 (C-4”), 147.3 (C-4’), 170.5 (Ac-CO); IR (neat, cm−1)
3383, 2945, 2854, 1730, 1375, 1248, 1032, 976, 833, 613. ESI-MS: 518 (M+H)+; Anal. Calcd for
C32H43N3O3: C, 74.24; H, 8.37; N, 8.12. Found: C, 74.38; H, 8.24; N, 8.19.
3β-Acetoxy-16β-[4-(3-tolyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6c): Alkyne: 3-tolyl-
acetylene (0.14 mL). After purification, 6c was obtained as a white solid (458 mg, 91%), mp 232-233
°C, Rf = 0.36 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.79 (s, 3H, 18-CH3), 0.95 (m, 1H), 1.01 (s, 3H, 19-
CH3), 1.08-1.21 (overlapping m, 3H), 1.33-1.61 (overlapping m, 6H), 1.79-1.90 (overlapping m, 4H),
1.95 (dd, 1H, J = 12.0 Hz, J = 3.0 Hz), 2.02 (s, 3H, Ac-CH3), 2.31 (m, 2H, 4-H2), 2.38 (s, 3H, 3”-CH3),
2.72 (m, 1H, 16-H), 3.87 (d, 1H, J = 10.0 Hz, 17-H), 4.30 (dd, 1H, J = 13.5 Hz, J = 6.5 Hz, 16a-H),
4.58 (m, 1H, 3-H), 4.69 (dd, 1H, J = 14.0 Hz, J = 6.5 Hz, 16a-H), 5.33 (d, 1H, J = 4.0 Hz, 6-H), 7.13
(d, 1H, J = 7.0 Hz, 4”-H), 7.29 (t, 1H, J = 7.5 Hz, 5”-H), 7.57 (d, 1H, J = 7.5 Hz, 6”-H), 7.65 (s, 1H,
13
2”-H), 7.81 (s, 1H, 5’-H); C-NMR (CDCl3); δ [ppm] = 12.3 (C-18), 19.3 (C-19), 20.4 (C-11), 21.4
(Ac-CH3), 27.7, 29.6, 31.0, 31.1, 31.6, 36.6, 37.0, 37.3, 38.0, 41.3, 43.7, 49.8, 50.0, 52.0, 73.8 (C-3),
80.6 (C-17), 120.6 (C-5’), 122.0 (C-6), (122.7, 126.3, 128.7, 128.9): (4C, C-2”, C-4”, C-5” and C-6”),
130.2 (C-1”), 138.5 (C-3”), 139.7 (C-5), 147.3 (C-4’), 170.6 (Ac-CO); IR (neat, cm−1) 3406, 2922,
2850, 1731, 1364, 1244, 1024, 787, 696. ESI-MS: 504 (M+H)+; Anal. Calcd for C31H41N3O3: C, 73.92;
H, 8.20; N, 8.34. Found: C, 73.80; H, 8.38; N, 8.49.
3β-Acetoxy-16β-[4-(4-tert-butylphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6d): Alkyne:
4-tert-butylphenylacetylene (0.2 mL). After purification, 6d was obtained as a white solid (507 mg,
1
93%), mp 318-319 °C, Rf = 0.39 (ss B); H-NMR (CDCl3); δ [ppm] = 0.79 (s, 3H, 18-CH3), 0.88

Molecules 2011, 16
4795
(m, 1H), 1.02 (s, 3H, 19-CH3), 1.34 (s, 9H, 3 x tBu-CH3), 1.11-1.20 (overlapping m, 3H), 1.37-1.60
(overlapping m, 6H), 1.79-1.91 (overlapping m, 4H), 1.96 (dd, 1H, J = 11.5 Hz, J = 2.5 Hz), 2.03 (s,
3H, Ac-CH3), 2.31 (m, 2H, 4-H2), 2.75 (m, 1H, 16-H), 3.89 (d, 1H, J = 10.0 Hz, 17-H), 4.31 (m, 1H,
16a-H), 4.60 (m, 1H, 3-H), 4.72 (dd, 1H, J = 13.5 Hz, J = 6.5 Hz, 16a-H), 5.34 (d, 1H, J = 4.0 Hz,
6-H), 7.45 (d, 2H, J = 6.0 Hz, 3”- and 5”-H), 7.78 (d, 2H, J = 6.0 Hz, 2”- and 6”-H), 7.87 (s, 1H,
5’-H); 13C-NMR (CDCl3); δ [ppm] = 12.3 (C-18), 19.3 (C-19), 20.5 (C-11), 21.4 (Ac-CH3), 27.7, 29.7,
30.9, 31.1, 31.3 (3C, 3 x tBu-CH3), 31.6, 36.6, 37.0, 37.3, 38.0, 41.3, 43.8, 49.9, 50.0, 52.1, 73.7 (C-3),
80.6 (C-17), 120.4 (C-5’), 122.0 (C-6), 125.5 (2C), 125.8 (2C), 127.3 (C-1”), 139.7 (C-5), 147.1
(C-4’), 151.4 (C-4”), 170.5 (Ac-CO); IR (neat, cm−1) 3441, 2949, 2903, 1730, 1454, 1366, 1247, 1034,
837, 810, 557. ESI-MS: 546 (M+H)+; Anal. Calcd for C34H47N3O3: C, 74.83; H, 8.68; N, 7.70. Found:
C, 75.02; H, 8.61; N, 7.82.
3β-Acetoxy-16β-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6e): Alkyne:
4-methoxyphenylacetylene (145 mg). After purification, 6e was obtained as a white solid (447 mg,
86%), mp 241-242 °C, Rf = 0.34 (ss B); 1H-NMR (500 MHz, 10% MeOD/CDCl3); δ [ppm] = 0.81 (s,
3H, 18-CH3), 0.93 (m, 1H), 1.03 (s, 3H, 19-CH3), 1.09-1.21 (overlapping m, 3H), 1.33-1.62
(overlapping m, 6H), 1.77-1.90 (overlapping m, 4H), 1.97 (dd, 1H, J = 12.0 Hz, J = 2.5 Hz), 2.03 (s,
3H, Ac-CH3), 2.32 (m, 2H, 4-H2), 2.72 (m, 1H, 16-H), 3.82 (d, 1H, J = 10.0 Hz, 17-H), 3.86 (s, 3H,
OCH3), 4.28 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H), 4.58 (m, 1H, 3-H), 4.70 (dd, 1H, J = 13.5 Hz,
J = 6.0 Hz, 16a-H), 5.34 (br s, 1H, 6-H), 6.96 (d, 2H, J = 8.5 Hz, 3”- and 5”-H), 7.21 (d, 2H, J = 8.5
Hz, 2”- and 6”-H), 7.81 (s, 1H, 5’-H); IR (neat, cm−1) 3398, 2935, 2902, 1728, 1499, 1373, 1244,
1063, 839, 538. ESI-MS: 520 (M+H)+; Anal. Calcd for C31H41N3O4: C, 71.65; H, 7.95; N, 8.09. Found:
C, 71.74; H, 7.76; N, 8.22.
3β-Acetoxy-16β-[4-(2-methoxyphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6f): Alkyne:
2-methoxyphenylacetylene (0.14 mL). After purification, 6f was obtained as a white solid (430 mg,
83%), mp 278-279 °C, Rf = 0.32 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.79 (s, 3H, 18-CH3), 0.94 (m,
1H), 1.01 (s, 3H, 19-CH3), 1.08-1.20 (overlapping m, 3H), 1.33-1.60 (overlapping m, 6H), 1.79-1.96
(overlapping m, 5H), 2.02 (s, 3H, Ac-CH3), 2.31 (m, 2H, 4-H2), 2.73 (m, 1H, 16-H), 3.87 (d, 1H, J =
10.0 Hz, 17-H), 3.92 (s, 3H, OCH3), 4.30 (dd, 1H, J = 13.5 Hz, J = 6.5 Hz, 16a-H), 4.58 (m, 1H, 3-H),
4.70 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.34 (br s, 1H, 6-H), 6.95 (d, 1H, J = 8.0 Hz, 3”-H),
7.06 (t, 1H, J = 7.5 Hz, 5”-H), 7.29 (t, 1H, J = 7.5 Hz, 4”-H), 8.05 (s, 1H, 5’-H), 8.31 (d, 1H, J = 7.5
Hz, 6”-H); 13C-NMR (CDCl3); δ [ppm] = 12.3 (C-18), 19.3 (C-19), 20.5 (C-11), 21.4 (Ac-CH3), 27.7,
31.0, 31.1, 31.6, 36.6, 37.0, 37.3, 38.0, 41.3, 43.7, 49.9, 50.0, 51.8, 55.3 (OCH3), 73.8 (C-3), 80.6
(C-17), 110.7, 119.2 (C-1”), 120.9 (C-5’), 122.0 (C-6), 123.9, 127.5, 128.8, 139.7 (C-5), 142.7 (C-4’),
155.5 (C-2”), 170.6 (Ac-CO); IR (neat, cm−1) 3400, 2939, 2907, 1732, 1491, 1373, 1246, 1060, 974,
750, 679. ESI-MS: 520 (M+H)+; Anal. Calcd for C31H41N3O4: C, 71.65; H, 7.95; N, 8.09. Found: C,
71.76; H, 8.08; N, 8.01.
3β-Acetoxy-16β-[4-(4-fluorophenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6g): Alkyne:
4-fluorophenylacetylene (0.13 mL). After purification, 6g was obtained as a white solid (430 mg,
1
85%), mp 263-264 °C, Rf = 0.36 (ss B); H-NMR (10% MeOD/CDCl3); δ [ppm] = 0.82 (s, 3H,

Molecules 2011, 16
4796
18-CH3), 0.96 (m, 1H), 1.03 (s, 3H, 19-CH3), 1.10-1.22 (overlapping m, 3H), 1.40-1.63 (overlapping
m, 6H), 1.78-1.91 (overlapping m, 4H), 1.97 (dd, 1H, J = 13.0 Hz, J = 2.5 Hz), 2.04 (s, 3H, Ac-CH3),
2.32 (m, 2H, 4-H2), 2.72 (m, 1H, 16-H), 3.84 (d, 1H, J = 10.0 Hz, 17-H), 4.30 (dd, 1H, J = 13.5 Hz,
J = 8.0 Hz, 16a-H), 4.58 (m, 1H, 3-H), 4.71 (dd, 1H, J = 13.5 Hz, J = 6.0 Hz, 16a-H), 5.34 (br s, 1H,
6-H), 7.11 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.76 (t, 2H, J = 7.5 Hz, 2”- and 6”-H), 7.88 (s, 1H, 5’-H);
13C-NMR (10% MeOD/CDCl3); δ [ppm] = 12.1 (C-18), 19.1 (C-19), 20.3 (C-11), 21.2 (Ac-CH3), 27.5,
30.9, 31.0, 31.4, 36.5, 36.8, 37.1, 37.8, 41.0, 43.5, 49.8, 49,9, 52.4, 73.9 (C-3), 80.3 (C-17), 115.7 (d,
2C, J = 21.5 Hz, C-3” and C-5”), 120.4 (C-5’), 122.0 (C-6), 126.5 (C-1”), 127.2 (d, 2C, J = 8 Hz, C-2”
and C-6”), 139.5 (C-5), 146.4 (C-4’), 162.5 (d, J = 245 Hz, C-4”), 170.9 (Ac-CO); IR (neat, cm−1)
3412, 2945, 2912, 1730, 1460, 1243, 1062, 812, 524. ESI-MS: 508 (M+H)+; Anal. Calcd for
C30H38FN3O3: C, 70.98; H, 7.55; N, 8.28. Found: C, 70.86; H, 7.64; N, 8.43.
3β-Acetoxy-16β-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6h): Alkyne: 3-
aminophenylacetylene (0.12 mL). After purification, 6h was obtained as a white solid (454 mg, 90%),
mp 255-256 °C, Rf = 0.30 (ss C); 1H-NMR (DMSO-d6); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.91 (m, 2H),
0.98 (s, 3H, 19-CH3), 1.02-1.15 (overlapping m, 3H), 1.38-1.56 (overlapping m, 6H), 1.74-1.90
(overlapping m, 4H), 1.97 (s, 3H, Ac-CH3), 2.25 (m, 2H, 4-H2), 2.64 (m, 1H, 16-H), 3.71 (d, 1H, J =
10.0 Hz, 17-H), 4.17 (t, 1H, J = 12.5 Hz, 16a-H), 4.43 (m, 1H, 3-H), 4.57 (dd, 1H, J = 13.5 Hz, J = 5.0
Hz, 16a-H), 5.02 (br s, 1H, OH), 5.30 (br s, 1H, 6-H), 5.66 (br s, 2H, NH2), 6.56 (d, 1H, J = 7.0 Hz,
4”-H), 6.98 (d, 1H, J = 7.0 Hz, 6”-H), 7.08 (t, 1H, J = 7.5 Hz, 5”-H), 7.14 (s, 1H, 2”-H), 8.41 (s, 1H,
13
5’-H); C-NMR (DMSO-d6); δ [ppm] = 12.4 (C-18), 19.0 (C-19), 20.1 (C-11), 21.0 (Ac-CH3), 27.3,
30.4, 30.7, 31.0, 36.1, 36.4, 36.8, 37.6, 40.3, 43.2, 49.1, 49.6, 52.2, 73.1 (C-3), 79.4 (C-17), 110.9,
113.7, 113.9, 121.1, 121.9, 129.3, 131.4, 139.4, 146.5, 147.8, 169.7 (Ac-CO); IR (neat, cm−1) 3340,
3228, 2941, 1732, 1454, 1242, 1069, 1034, 795. ESI-MS: 505 (M+H)+; Anal. Calcd for C30H40N4O3:
C, 71.40; H, 7.99; N, 11.10. Found: C, 71.54; H, 7.86; N, 11.23.
3β-Acetoxy-16β-[4-(2-pyridyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-en-17β-ol (6i): Alkyne:
2
pyridylacetylene (0.11 mL). After purification, 6i was obtained as a white solid (427 mg, 87%), mp
1
259-260 °C, Rf = 0.23 (ss C); H-NMR (CDCl3); δ [ppm] = 0.80 (s, 3H, 18-CH3), 0.93 (m, 1H), 1.01
(s, 3H, 19-CH3), 1.16-1.27 (overlapping m, 3H), 1.39-1.59 (overlapping m, 6H), 1.77-1.87
(overlapping m, 4H), 1.94 (dd, 1H, J = 12.5 Hz, J = 2.5 Hz), 2.01 (s, 3H, Ac-CH3), 2.30 (m, 2H, 4-H2),
2.72 (m, 1H, 16-H), 3.87 (d, 1H, J = 10.0 Hz, 17-H), 4.34 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H),
4.57 (m, 1H, 3-H), 4.75 (dd, 1H, J = 13.5 Hz, J = 6.5 Hz, 16a-H), 5.32 (d, 1H, J = 3.0 Hz, 6-H), 7.24
(m, 1H, 4”-H), 7.79 (t, 1H, J = 7.5 Hz, 5”-H), 8.17 (d, 1H, J = 7.5 Hz, 6”-H), 8.30 (s, 1H, 5’-H), 8.54
13
(d, 1H, J = 3.0 Hz, 3”-H); C-NMR (CDCl3); δ [ppm] = 12.3 (C-18), 19.3 (C-19), 20.4 (C-11), 21.4
(Ac-CH3), 27.7, 31.0, 31.1, 31.6, 36.6, 37.0, 37.3, 38.0, 41.3, 43.7, 49.8, 50.0, 52.4, 73.8 (C-3), 80.5
(C-17), 120.4 (C-5’), 122.1 (C-6), 122.8, 123.1, 137.4, 139.6 (C-5), 147.3 (C-2”), 148.8 (C-6”), 149.9
(C-4’), 170.5 (Ac-CO); IR (neat, cm−1) 3395, 2932, 2911, 1731, 1435, 1364, 1240, 1032, 789, 540.
ESI-MS: 491 (M+H)+; Anal. Calcd for C29H38N4O3: C, 70.99; H, 7.81; N, 11.42. Found: C, 71.16; H,
7.97; N, 11.61.

Molecules 2011, 16
4797
3β-Acetoxy-16β-(4-cyclopropyl-1H-1,2,3-triazol-1-ylmethyl)androst-5-en-17β-ol (6j): Alkyne: cyclo-
propylacetylene (0.09 mL). After purification, 6j was obtained as a white solid (355 mg, 78%), mp
261-263 °C, Rf = 0.30 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.83 (m, 2H), 0.90-
0.96 (overlapping m, 4H), 1.01 (s, 3H, 19-CH3), 1.08-1.17 (overlapping m, 3H), 1.41-1.61
(overlapping m, 5H), 1.76-1.95 (overlapping m, 5H), 2.02 (s, 3H, Ac-CH3), 2.31 (m, 2H, 4-H2), 2.63
(m, 1H, 16-H), 3.08 (br s, 1H, 1”-H), 3.84 (dd, 1H, J = 10.0 Hz, J = 3.5 Hz, 17-H), 4.19 (dd, 1H, J =
13.5 Hz, J = 6.5 Hz, 16a-H), 4.57-4.61 (overlapping m, 2H, 3- and 16a-H), 5.33 (d, 1H, J = 3.5 Hz,
13
6-H), 7.28 (s, 1H, 5’-H); C-NMR (CDCl3); δ [ppm] = 6.6, 7.7 (2C), 12.3 (C-18), 19.3 (C-19), 20.5
(C-11), 21.4 (Ac-CH3), 27.7, 31.0, 31.1, 31.6, 36.6, 37.0, 37.3, 38.0, 41.4, 43.7, 49.9, 50.0, 51.7, 73.8
(C-3), 80.5 (C-17), 120.5 (C-5’), 122.1 (C-6), 139.7 (C-5), 149.9 (C-4’), 170.5 (Ac-CO); IR
(neat, cm−1) 3394, 2943, 1732, 1431, 1372, 1246, 1068, 1034, 814. ESI-MS: 454 (M+H)+; Anal. Calcd
for C27H39N3O3: C, 71.49; H, 8.67; N, 9.26. Found: C, 71.61; H, 8.82; N, 9.57.
3.7. General procedure for preparation of 16β-(4-phenyl-, substituted 4-phenyl- or 4-cycloalkyl-1H-
1,2,3-triazol-1-ylmethyl)androst-5-ene-3β,17β-diols 7a-j
Compounds 6a-j (0.5 mmol) were deacetylated by dissolving in MeOH (20 mL), adding KOH
(150 mg, 2.7 mmol), stirring the mixture for 1 h at 50 °C, and then pouring into water (200 mL) and
neutralizing with diluted HCl. The resulting precipitate was filtered off, washed with water and dried.
The crude product obtained was purified by flash chromatography (silica gel) to afford 7a-j.
16β-(4-Phenyl-1H-1,2,3-triazol-1-ylmethyl)androst-5-ene-3β,17β-diol (7a): Eluent: CH2Cl2/EtOAc
(75:25), yielding 7a as a white solid (184 mg, 82%), mp 264-265 °C, Rf = 0.45 (ss C); 1H-NMR (10%
MeOD/CDCl3); δ [ppm] = 0.82 (s, 3H, 18-CH3), 0.94-0.98 (m, 2H), 1.02 (s, 3H, 19-CH3), 1.09-1.25
(overlapping m, 3H), 1.45-1.61 (overlapping m, 5H), 1.81-1.97 (overlapping m, 5H), 2.20-2.28 (m,
2H), 2.73 (m, 1H, 16-H), 3.47 (m, 1H, 3-H), 3.84 (d, 1H, J = 10.0 Hz, 17-H), 4.30 (dd, 1H, J = 13.5
Hz, J = 8.0 Hz, 16a-H), 4.72 (dd, 1H, J = 13.5 Hz, J = 6.0 Hz, 16a-H), 5.31 (br s, 1H, 6-H), 7.34 (t,
1H, J = 7.5 Hz, 4”-H), 7.43 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.79 (d, 2H, J = 7.5 Hz, 2”- and 6”-H),
7.89 (s, 1H, 5’-H); IR (neat, cm−1) 3428, 2944, 2904, 1444, 1236, 1080, 827, 760, 691. ESI-MS: 448
(M+H)+; Anal. Calcd for C28H37N3O2: C, 75.13; H, 8.33; N, 9.39. Found: C, 75.27; H, 8.21; N, 9.56.
16β-[4-(4-Ethylphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol (7b): Eluent: CH2Cl2/
1
EtOAc (75:25), yielding 7b as a white solid (192 mg, 81%), mp 261-262 °C, Rf = 0.48 (ss C); H-
NMR (DMSO-d6); δ [ppm] = 0.75 (s, 3H, 18-CH3), 0.83-0.88 (m, 2H), 0.94 (s, 3H, 19-CH3), 1.03-1.12
(overlapping m, 3H), 1.19 (t, 3H, J = 7.5 Hz, Et-CH3), 1.30-1.44 (overlapping m, 4H), 1.52 (m, 2H),
1.66 (m, 1H), 1.74-1.86 (overlapping m, 3H), 2.05-2.14 (m, 2H), 2.59 (q, 2H, J = 7.5 Hz, Et-CH2),
2.65 (m, 1H, 16-H), 3.24 (m, 1H, 3-H), 3.71 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz, 17-H), 4.18 (m, 1H,
16a-H), 4.58 (overlapping m, 2H, 3-OH and 16a-H), 5.01 (d, 1H, J = 3.5 Hz, 17-OH), 5.21 (br s, 1H,
6-H), 7.26 (d, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.74 (d, 2H, J = 7.5 Hz, 2”- and 6”-H), 8.51 (s, 1H,
5’-H); IR (neat, cm−1) 3383, 2943, 1440, 1240, 1082, 1051, 812, 738, 644. ESI-MS: 476 (M+H)+;
Anal. Calcd for C30H41N3O2: C, 75.75; H, 8.69; N, 8.83. Found: C, 75.91; H, 8.87; N, 8.70.

Molecules 2011, 16
4798
16β-[4-(3-Tolyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol (7c): Eluent: CH2Cl2/EtOAc
1
(75:25), yielding 7c as a white solid (203 mg, 88%), mp 237-238 °C, Rf = 0.44 (ss C); H-NMR
(DMSO-d6); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.86 (m, 2H), 0.94 (s, 3H, 19-CH3), 1.04-1.17
(overlapping m, 3H), 1.31-1.43 (overlapping m, 4H), 1.51 (m, 2H), 1.65 (m, 1H), 1.73-1.87
(overlapping m, 3H), 2.07-2.15 (m, 2H), 2.34 (s, 3H, 3”-CH3), 2.64 (m, 1H, 16-H), 3.24 (m, 1H, 3-H),
3.71 (dd, 1H, J = 9.5 Hz, J = 4.0 Hz, 17-H), 4.19 (m, 1H, 16a-H), 4.59 (overlapping m, 2H, 3-OH and
16a-H), 5.00 (d, 1H, J = 4.0 Hz, 17-OH), 5.21 (br s, 1H, 6-H), 7.12 (d, 1H, J = 7.0 Hz, 4”-H), 7.31
(t, 1H, J = 7.5 Hz, 5”-H), 7.62 (d, 1H, J = 7.0 Hz, 6”-H), 7.66 (s, 1H, 2”-H), 8.53 (s, 1H, 5’-H); IR
(neat, cm−1) 3339, 3237, 2931, 1452, 1232, 1049, 787, 696. ESI-MS: 462 (M+H)+; Anal. Calcd for
C29H39N3O2: C, 75.45; H, 8.52; N, 9.10. Found: C, 75.57; H, 8.67; N, 9.32.
16β-[4-(4-Tert-butylphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol (7d): Eluent:
CH2Cl2/EtOAc (75:25), yielding 7d as a white solid (214 mg, 85%), mp 284-285 °C, Rf = 0.49 (ss C);
1H-NMR (10% MeOD/CDCl3); δ [ppm] = 0.75 (s, 3H, 18-CH3), 0.85-0.89 (m, 2H), 0.94 (s, 3H, 19-
CH3), 1.27 (s, 9H, 3 x tBu-CH3), 0.99-1.13 (overlapping m, 3H), 1.40-1.53 (overlapping m, 5H), 1.70-
1.89 (overlapping m, 5H), 2.14-2.21 (m, 2H), 2.66 (m, 1H, 16-H), 3.40 (m, 1H, 3-H), 3.76 (d, 1H, J =
10.0 Hz, 17-H), 4.21 (dd, 1H, J = 14.0 Hz, J = 8.5 Hz, 16a-H), 4.64 (dd, 1H, J = 13.5 Hz, J = 6.0 Hz,
16a-H), 5.24 (br s, 1H, 6-H), 7.38 (d, 2H, J = 8.0 Hz, 3”- and 5”-H), 7.64 (d, 2H, J = 8.0 Hz, 2”- and
6”-H), 7.79 (s, 1H, 5’-H); IR (neat, cm−1) 3477, 2949, 1460, 1215, 1070, 1047, 818, 559. ESI-MS: 504
(M+H)+; Anal. Calcd for C32H45N3O2: C, 76.30; H, 9.00; N, 8.34. Found: C, 76.17; H, 8.82; N, 8.56.
16β-[4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol
(7e):
Eluent:
CH2Cl2/EtOAc (70:30), yielding 7e as a white solid (205 mg, 86%), mp 262-264 °C, Rf = 0.39 (ss C);
1H-NMR (DMSO-d6); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.86-0.90 (m, 2H), 0.95 (s, 3H, 19-CH3), 1.03-
1.18 (overlapping m, 3H), 1.33-1.43 (overlapping m, 4H), 1.52 (m, 2H), 1.66 (m, 1H), 1.75-1.87
(overlapping m, 3H), 2.08-2.14 (m, 2H), 2.64 (m, 1H, 16-H), 3.24 (m, 1H, 3-H), 3.71 (dd, 1H, J = 9.5
Hz, J = 3.0 Hz, 17-H), 3.79 (s, 3-H, 4”-OCH3), 4.17 (m, 1H, 16a-H), 4.58 (overlapping m, 2H, 3-OH
and 16a-H), 4.98 (d, 1H, J = 3.0 Hz, 17-OH), 5.21 (br s, 1H, 6-H), 7.00 (d, 2H, J = 8.5 Hz, 3”- and
5”-H), 7.75 (d, 2H, J = 8.5 Hz, 2”- and 6”-H), 8.44 (s, 1H, 5’-H); IR (neat, cm−1) 3454, 3206, 2930,
1499, 1250, 1068, 1028, 833, 667. ESI-MS: 478 (M+H)+; Anal. Calcd for C29H39N3O3: C, 72.92; H,
8.23; N, 8.80. Found: C, 73.11; H, 8.05; N, 8.97
16β-[4-(2-Methoxyphenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol
(7f):
Eluent:
CH2Cl2/EtOAc (70:30), yielding 7f as a white solid (208 mg, 87%), mp 219-220 °C, Rf = 0.46 (ss C);
1H-NMR (DMSO-d6); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.86 (m, 2H), 0.94 (s, 3H, 19-CH3), 1.02-1.15
(overlapping m, 3H), 1.32-1.41 (overlapping m, 4H), 1.50 (m, 2H), 1.66 (m, 1H), 1.74-1.85
(overlapping m, 3H), 2.09-2.13 (m, 2H), 2.65 (m, 1H, 16-H), 3.24 (m, 1H, 3-H), 3.70 (dd, 1H, J = 9.5
Hz, J = 3.0 Hz, 17-H), 3.90 (s, 3H, 2”-OCH3), 4.22 (m, 1H, 16a-H), 4.59 (overlapping m, 2H, 3-OH
and 16a-H), 4.97 (d, 1H, J = 3.0 Hz, 17-OH), 5.20 (br s, 1H, 6-H), 7.03 (t, 1H, J = 7.0 Hz, 5”-H), 7.10
(d, 1H, J = 8.0 Hz, 3”-H), 7.31 (t, 1H, J = 7.0 Hz, 4”-H), 8.13 (d, 1H, J = 7.5 Hz, 6”-H), 8.39 (s, 1H,
5’-H); IR (neat, cm−1) 3408, 3252, 2941, 1489, 1246, 1045, 1020, 752. ESI-MS: 478 (M+H)+; Anal.
Calcd for C29H39N3O3: C, 72.92; H, 8.23; N, 8.80. Found: C, 73.10; H, 8.39; N, 8.59.

Molecules 2011, 16
4799
16β-[4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol (7g): Eluent: CH2Cl2/
EtOAc (70:30), yielding 7g as a white solid (212 mg, 91%), mp 282-283 °C, Rf = 0.43 (ss C); 1H-NMR
(DMSO-d6); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.87 (m, 2H), 0.95 (s, 3H, 19-CH3), 1.04-1.14
(overlapping m, 3H), 1.30-1.43 (overlapping m, 4H), 1.53 (m, 2H), 1.64 (m, 1H), 1.75-1.87
(overlapping m, 3H), 2.07-2.14 (m, 2H), 2.63 (m, 1H, 16-H), 3.24 (m, 1H, 3-H), 3.71 (d, 1H, J = 9.5
Hz, 17-H), 4.18 (m, 1H, 16a-H), 4.60 (m, 1H, 16a-H), 5.22 (br s, 1H, 6-H), 7.27 (t, 2H, J = 8.0 Hz,
3”- and 5”-H), 7.86 (t, 2H, J = 8.0 Hz, 2”- and 6”-H), 8.57 (s, 1H, 5’-H); IR (neat, cm−1) 3426, 2941,
1558, 1495, 1231, 1051, 817, 607. ESI-MS: 466 (M+H)+; Anal. Calcd for C28H36FN3O2: C, 72.23; H,
7.79; N, 9.02. Found: C, 72.44; H, 7.66; N, 8.84.
16β-[4-(3-Aminophenyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol (7h): Eluent: CH2Cl2/
1
EtOAc (50:50), yielding 7h as a white solid (190 mg, 82%), mp 227-228 °C, Rf = 0.22 (ss C); H-
NMR (DMSO-d6); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.89 (m, 2H), 0.95 (s, 3H, 19-CH3), 1.05-1.13
(overlapping m, 3H), 1.34-1.52 (overlapping m, 6H), 1.66 (m, 1H), 1.76-1.89 (overlapping m, 3H),
2.07-2.12 (m, 2H), 2.63 (m, 1H, 16-H), 3.24 (m, 1H, 3-H), 3.70 (dd, 1H, J = 9.5 Hz, J = 3.0 Hz, 17-H),
4.18 (m, 1H, 16a-H), 4.57 (overlapping m, 2H, 3-OH and 16a-H), 4.98 (d, 1H, J = 3.0 Hz, 17-OH),
5.13 (br s, 2H, NH2), 5.21 (br s, 1H, 6-H), 6.51 (d, 1H, J = 7.0 Hz, 4”-H), 6.92 (d, 1H, J = 7.0 Hz,
6”-H), 7.05 (t, 1H, J = 7.0 Hz, 5”-H), 7.08 (s, 1H, 2”-H), 8.39 (s, 1H, 5’-H); IR (neat, cm−1) 3558,
3373, 2936, 1585, 1439, 1066, 1046, 790, 586. ESI-MS: 463 (M+H)+; Anal. Calcd for C28H38N4O2: C,
72.69; H, 8.28; N, 12.11. Found: C, 72.86; H, 8.45; N, 12.39.
16β-[4-(2-Pyridyl)-1H-1,2,3-triazol-1-ylmethyl]androst-5-ene-3β,17β-diol (7i): Eluent: CH2Cl2/
EtOAc (50:50), yielding 7i as a white solid (202 mg, 90%), mp 240-241 °C, Rf = 0.26 (ss C); 1H-NMR
(10% MeOD/CDCl3); δ [ppm] = 0.76 (s, 3H, 18-CH3), 0.85 (m, 2H), 0.95 (s, 3H, 19-CH3), 1.04-1.14
(overlapping m, 3H), 1.37-1.53 (overlapping m, 6H), 1.60 (m, 1H), 1.79-1.91 (overlapping m, 3H),
2.13-2.20 (m, 2H), 2.64 (m, 1H, 16-H), 3.41 (m, 1H, 3-H), 3.76 (d, 1H, J = 10.0 Hz, 17-H), 4.27 (dd,
1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H), 4.67 (dd, 1H, J = 13.5 Hz, J = 6.0 Hz, 16a-H), 5.24 (br s, 1H,
6-H), 7.21 (m, 1H, 4”-H), 7.76 (t, 1H, J = 7.5 Hz, 5”-H), 8.09 (d, 1H, J = 7.5 Hz, 6”-H), 8.22 (s, 1H,
5’-H), 8.46 (d, 1H, J = 3.0 Hz, 3”-H); IR (neat, cm−1) 3331, 2929, 1599, 1460, 1263, 1072, 787, 577.
ESI-MS: 449 (M+H)+; Anal. Calcd for C27H36N4O2: C, 72.29; H, 8.09; N, 12.49. Found: C, 72.40; H,
8.22; N, 12.41.
16β-(4-Cyclopropyl-1H-1,2,3-triazol-1-ylmethyl)androst-5-ene-3β,17β-diol (7j): Eluent: CH2Cl2/
EtOAc (75:25), yielding 7j as a white solid (170 mg, 83%), mp 235-236 °C, Rf = 0.47 (ss C); 1H-NMR
(DMSO-d6); δ [ppm] = 0.67 (m, 2H), 0.72 (s, 3H, 18-CH3), 0.81-0.89 (overlapping m, 4H), 0.94 (s,
3H, 19-CH3), 1.02-1.13 (overlapping m, 3H), 1.31-1.53 (overlapping m, 6H), 1.66 (m, 1H), 1.77-1.91
(overlapping m, 3H), 2.08-2.14 (m, 2H), 2.57 (m, 1H, 16-H), 3.24 (m, 1H, 3-H), 3.67 (dd, 1H, J = 9.5
Hz, J = 3.5 Hz, 17-H), 4.05 (m, 1H, 16a-H), 4.46 (m, 1H, 16a-H), 4.61 (br s, 1H, 3-OH), 4.95 (d, 1H,
J = 3.5 Hz, 17-OH), 5.23 (br s, 1H, 6-H), 7.79 (s, 1H, 5’-H); IR (neat, cm−1) 3401, 3251, 2937, 1433,
1219, 1049, 808, 588. ESI-MS: 412 (M+H)+; Anal. Calcd for C25H37N3O2: C, 72.95; H, 9.06; N, 10.21.
Found: C, 73.19; H, 9.27; N, 10.36.

Molecules 2011, 16
4800
3.8. General procedure for preparation of 3β-acetoxy-16β-(5-substituted-1H-tetrazol-1-ylmethyl)-
androst-5-en-17β-ols 9a-e
Compound 5 (387 mg, 1 mmol) was dissolved in CH2Cl2 (5 mL), and Cu2(OTf)2·C6H6 (50 mg,
10 mol %) was added as catalyst. The appropriate nitrile (1.1 mmol) was added to the reaction mixture,
which was then stirred for 48 h at ambient temperature. The progress of the reactions was monitored
by TLC, and the solvent was then evaporated in vacuo. The resulting crude product was purified by
flash chromatography with CH2Cl2/EtOAc (95:5) as eluent.
3β-Acetoxy-16β-(5-methoxycarbonyl-1H-tetrazol-1-ylmethyl)androst-5-en-17β-ol (9a): Nitrile: methyl
cyanoformate (8a, 0.09 mL) was added to the mixture. After purification, 9a was obtained as a white
solid (310 mg, 66%), mp 168-171 °C, Rf = 0.47 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.85 (s, 3H, 18-
CH3), 0.90-0.97 (overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.09-1.22 (overlapping m, 3H), 1.44-1.58
(overlapping m, 5H), 1.71 (m, 1H), 1.83-1.86 (overlapping m, 3H), 1.94 (m, 1H), 2.01 (s, 3H,
Ac-CH3), 2.30 (m, 2H, 4-H2), 2.86 (m, 1H, 16-H), 3.84 (d, 1H, J = 9.5 Hz, 17-H), 4.05 (s, 3H, OCH3),
4.57 (m, 1H, 3-H), 4.66 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H), 5.04 (dd, 1H, J = 13.5 Hz, J = 7.0
13
Hz, 16a-H), 5.34 (d, 1H, J = 4.0 Hz, 6-H); C-NMR (CDCl3); δ [ppm] = 11.8 (C-18), 18.9 (C-19),
20.1 (C-11), 21.0 (Ac-CH3), 27.3, 30.0, 30.8, 31.1, 36.2, 36.6, 36.7, 37.6, 39.8, 43.4, 49.4, 49.6, 51.0,
53.3 (OCH3), 73.4 (C-3), 80.5 (C-17), 121.6 (C-6), 139.4 (C-5), 145.4 (C-5’), 156.8, 170.2 (Ac-CO);
IR (neat, cm−1) 3501, 2934, 1742, 1703, 1427, 1254, 1032, 826, 691. ESI-MS: 473 (M+H)+; Anal.
Calcd for C25H36N4O5: C, 63.54; H, 7.68; N, 11.86. Found: C, 63.75; H, 7.57; N, 12.03.
3β-Acetoxy-16β-(5-ethoxycarbonyl-1H-tetrazol-1-ylmethyl)androst-5-en-17β-ol (9b): Nitrile: ethyl
cyanoformate (8b, 0.11 mL) was added to the mixture. After purification, 9b was obtained as a white
1
solid (350 mg, 72%), mp 172-174 °C, Rf = 0.59 (ss B); H-NMR (CDCl3); δ [ppm] = 0.84 (s, 3H,
18-CH3), 0.91-0.96 (overlapping m, 2H), 1.01 (s, 3H, 19-CH3), 1.08-1.16 (overlapping m, 2H), 1.21
(m, 1H), 1.45 (t, 3H, J = 7.0 Hz, OEt-CH3), 1.47-1.58 (overlapping m, 5H), 1.70 (m, 1H), 1.82-1.86
(overlapping m, 3H), 1.92 (m, 1H), 2.01 (s, 3H, Ac-CH3), 2.30 (m, 2H, 4-H2), 2.85 (m, 1H, 16-H),
3.84 (d, 1H, J = 9.5 Hz, 17-H), 4.51 (q, 2H, J = 7.0 Hz, OEt-CH2), 4.56 (m, 1H, 3-H), 4.66 (dd, 1H,
J = 13.5 Hz, J = 8.5 Hz, 16a-H), 5.03 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.33 (d, 1H,
13
J = 4.0 Hz, 6-H); C-NMR (CDCl3); δ [ppm] = 12.2 (C-18), 14.0, 19.3 (C-19), 20.4 (C-11), 21.4
(Ac-CH3), 27.6, 30.3, 31.1, 31.5, 36.6, 36.9, 37.1, 38.0, 40.2, 43.8, 49.7, 50.0, 51.3, 63.4, 73.7 (C-3),
80.8 (C-17), 121.9 (C-6), 139.7 (C-5), 145.9 (C-5’), 156.8, 170.5 (Ac-CO); IR (neat, cm−1) 3428, 2918,
1743, 1721, 1470, 1240, 1020, 854. ESI-MS: 487 (M+H)+; Anal. Calcd for C26H38N4O5: C, 64.18; H,
7.87; N, 11.51. Found: C, 64.32; H, 7.67; N, 11.66.
3β-Acetoxy-16β-(5-benzyloxycarbonyl-1H-tetrazol-1-ylmethyl)androst-5-en-17β-ol
(9c):
Nitrile:
benzyl cyanoformate (8c 0.16 mL) was added to the mixture. After purification, 9c was obtained as a
1
white solid (340 mg, 62%), mp 153-156 °C, Rf = 0.21 (ss A); H-NMR (CDCl3); δ [ppm] = 0.78
(s, 3H, 18-CH3), 0.88-0.95 (overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.08-1.15 (overlapping m, 3H),
1.43-1.57 (overlapping m, 5H), 1.66 (m, 1H), 1.78-1.86 (overlapping m, 3H), 1.96 (m, 1H), 2.01 (s,
3H, Ac-CH3), 2.31 (m, 2H, 4-H2), 2.79 (m, 1H, 16-H), 3.76 (d, 1H, J = 9.5 Hz, 17-H), 4.59-4.63
(overlapping m, 2H, 3- and 16a-H), 5.00 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.33 (d, 1H, J = 3.0

Molecules 2011, 16
4801
Hz, 6-H), 5.46 (dd, 2H, J = 21.5 Hz, J = 12.0 Hz, OCH2Ph), 7.37 (m, 3H, 3”-, 4”- and 5”-H), 7.46 (d,
13
2H, J = 7.0 Hz, 2”- and 6”-H); C-NMR (CDCl3); δ [ppm] = 12.1 (C-18), 19.3 (C-19), 20.4 (C-11),
21.4 (Ac-CH3), 27.6, 30.2, 31.1, 31.5, 36.6, 36.9, 37.1, 38.0, 40.2, 43.7, 49.7, 50.0, 51.3, 68.7, 73.7
(C-3), 80.8 (C-17), 122.0 (C-6), 128.7 (2C), 128.9 (2C), 129.0 (C-4”), 134.0 (C-1”), 139.7 (C-5), 145.9
(C-5’), 156.6, 170.5 (Ac-CO); IR (neat, cm−1) 3525, 2945, 1733, 1703, 1454, 1256, 1026, 748, 697.
ESI-MS: 549 (M+H)+; Anal. Calcd for C31H40N4O5: C, 67.86; H, 7.35; N, 10.21. Found: C, 67.98; H,
7.52; N, 10.12
3β-Acetoxy-16β-(5-acetyl-1H-tetrazol-1-ylmethyl)androst-5-en-17β-ol (9d): Nitrile: acetyl cyanide
(8d, 0.08 mL) was added to the mixture. After purification, 9d was obtained as a white solid (260 mg,
57%), mp 191-193 °C, Rf = 0.33 (ss A); 1H-NMR (CDCl3); δ [ppm] = 0.82 (s, 3H, 18-CH3), 0.91-0.97
(overlapping m, 2H), 1.01 (s, 3H, 19-CH3), 1.09-1.19 (overlapping m, 3H), 1.44-1.59 (overlapping m,
5H), 1.72 (m, 1H), 1.81-1.87 (overlapping m, 3H), 1.95 (m, 1H), 2.01 (s, 3H, Ac-CH3), 2.31 (m, 2H,
4-H2), 2.53 (s, 3H, 5’Ac-CH3), 2.84 (m, 1H, 16-H), 3.81 (d, 1H, J = 9.5 Hz, 17-H), 4.56 (m, 1H, 3-H),
4.64 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H), 5.02 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.33 (d,
1H, J = 3.5 Hz, 6-H); 13C-NMR (CDCl3); δ [ppm] = 11.9 (C-18), 19.1 (C-19), 20.2 (C-11), 20.6, 21.0
(Ac-CH3), 27.4, 30.2, 30.9, 31.3, 36.4, 36.8, 37.0, 37.8, 39.9, 43.6, 49.5, 49.9, 51.2, 73.5 (C-3), 80.7
(C-17), 121.7 (C-6), 139.6 (C-5), 147.7 (C-5’), 170.4 (Ac-CO), 190.4; IR (neat, cm−1) 3512, 2931,
1740, 1709, 1486, 1259, 1023, 896, 682. ESI-MS: 457 (M+H)+; Anal. Calcd for C25H36N4O4: C, 65.76;
H, 7.95; N, 12.27. Found: C, 65.61; H, 8.06; N, 12.51.
3β-Acetoxy-16β-(5-benzoyl-1H-tetrazol-1-ylmethyl)androst-5-en-17β-ol (9e): Nitrile: benzoyl cyanide
(8e, 145 mg) was added to the mixture. After purification, 9e was obtained as a white solid (280 mg,
54%), mp 182-185 °C, Rf = 0.30 (ss A); 1H-NMR (CDCl3); δ [ppm] = 0.81 (s, 3H, 18-CH3), 0.88-0.95
(overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.08-1.12 (overlapping m, 2H), 1.23 (m, 1H), 1.43-1.61
(overlapping m, 5H), 1.73-1.86 (overlapping m, 4H), 1.93 (m, 1H), 2.01 (s, 3H, Ac-CH3), 2.30 (m, 2H,
4-H2), 2.88 (m, 1H, 16-H), 3.82 (d, 1H, J = 9.5 Hz, 17-H), 4.57 (m, 1H, 3-H), 4.64 (dd, 1H, J = 13.5
Hz, J = 7.5 Hz, 16a-H), 5.03 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.33 (d, 1H, J = 4.0 Hz, 6-H),
7.54 (t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.69 (t, 1H, J = 7.5 Hz, 4”-H), 8.33 (d, 2H, J = 7.5 Hz, 2”- and
6”-H); 13C-NMR (CDCl3); δ [ppm] = 11.8 (C-18), 18.9 (C-19), 20.1 (C-11), 21.0 (Ac-CH3), 27.3, 30.0,
30.7, 31.1, 36.2, 36.6, 36.8, 37.6, 39.9, 43.4, 49.4, 49.6, 50.8, 73.4 (C-3), 80.7 (C-17), 121.6 (C-6),
128.4 (2C), 130.6 (2C), 134.5 (C-4”), 134.7 (C-1”), 139.3 (C-5), 149.5 (C-5’), 170.2 (Ac-CO), 181.8;
IR (neat, cm−1) 3533, 2938, 1728, 1702, 1595, 1265, 1026, 921, 692. ESI-MS: 519 (M+H)+; Anal.
Calcd for C30H38N4O4: C, 69.47; H, 7.38; N, 10.80. Found: C, 69.63; H, 7.21; N, 10.91.
3.9. 16β-Azidomethylandrost-5-ene-3β,17β-diol (10)
Compound 5 (1.94 g, 5 mmol) was dissolved in MeOH (80 mL), and KOH (750 mg, 13.5 mmol)
was added. The mixture was stirred for 1 h at room temperature, and then poured into water (800 mL)
and neutralized with diluted HCl. The resulting precipitate was filtered off, washed with water and
dried. The crude product obtained was purified by flash chromatography to afford 10 as a white solid
(1.43 g, 83%), mp 154-157 °C, Rf = 0.19 (ss A); 1H-NMR (CDCl3); δ [ppm] = 0.78 (s, 3H, 18-CH3),
0.93 (m, 1H), 1.02 (s, 3H, 19-CH3), 1.05-1.15 (overlapping m, 3H), 1.42-1.60 (overlapping m, 6H),

Molecules 2011, 16
4802
1.84-1.89 (overlapping m, 4H), 1.99 (m, 1H), 2.25-2.32 (m, 2H, 4-H2), 2.37 (m, 1H, 16-H), 3.29 (dd,
1H, J = 12.0 Hz, J = 6.5 Hz, 16a-H), 3.52 (m, 1H, 3-H), 3.57 (dd, 1H, J = 12.5 Hz, J = 7.5 Hz, 16a-H),
3.78 (dd, 1H, J = 9.5 Hz, J = 5.0 Hz, 17-H), 5.34 (d, 1H, J = 4.5 Hz, 6-H); 13C-NMR (CDCl3); δ [ppm]
= 12.1 (C-18), 19.4 (C-19), 20.6 (C-11), 30.6, 31.2, 31.6, 31.7, 36.6, 37.2, 37.5, 39.9, 42.2, 43.6, 50.0,
50.1, 53.3, 71.6 (C-3), 81.3 (C-17), 121.2 (C-6), 140.9 (C-5); IR (neat, cm−1) 3519, 2941, 2904, 2115,
1452, 1374, 1246, 1028. ESI-MS: 346 (M+H)+; Anal. Calcd for C20H31N3O2: C, 69.53; H, 9.04; N,
12.16. Found: C, 69.38; H, 9.16; N, 12.35.
3.10. General procedure for preparation of 16β-(5-substituted-1H-tetrazol-1-ylmethyl)androst-5-ene-
3β,17β-diols 11a-e
Compound 10 (345 mg, 1 mmol) was dissolved in CH2Cl2 (5 mL), and Cu2(OTf)2·C6H6 (50 mg,
10 mol %) was added as catalyst. The appropriate nitrile (1.1 mmol) was added to the reaction mixture,
which was then stirred for 48 h at ambient temperature. The progress of the reactions was monitored
by TLC, and the solvent was then evaporated in vacuo. The resulting crude product was purified by
flash chromatography with CH2Cl2/EtOAc (85:15) as eluent.
16β-(5-Methoxycarbonyl-1H-tetrazol-1-ylmethyl)androst-5-ene-3β,17β-diol (11a): Nitrile: methyl
cyanoformate (8a, 0.09 mL) was added to the mixture. After purification, 11a was obtained as a white
1
solid (255 mg, 59%), mp 183-185 °C, Rf = 0.19 (ss B); H-NMR (CDCl3); δ [ppm] = 0.86 (s, 3H,
18-CH3), 0.92-0.96 (overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.07-1.14 (overlapping m, 3H), 1.46-
1.58 (overlapping m, 5H), 1.73 (m, 1H), 1.83-1.87 (overlapping m, 3H), 1.95 (m, 1H), 2.25-2.31
(overlapping m, 2H), 2.87 (m, 1H, 16-H), 3.51 (m, 1H, 3-H), 3.85 (dd, 1H, J = 9.5 Hz, J = 3.5 Hz,
17-H), 4.06 (s, 3H, OCH3), 4.67 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H), 5.04 (dd, 1H, J = 13.5 Hz,
J = 7.0 Hz, 16a-H), 5.33 (d, 1H, J = 4.5 Hz, 6-H); ESI-MS: 431 (M+H)+; Anal. Calcd for C23H34N4O4:
C, 64.16; H, 7.96; N, 13.01. Found: C, 64.43; H, 7.80; N, 13.19.
16β-(5-Ethoxycarbonyl-1H-tetrazol-1-ylmethyl)androst-5-ene-3β,17β-diol (11b): Nitrile: ethyl
cyanoformate (8b, 0.11 mL) was added to the mixture. After purification, 11b was obtained as a white
solid (285 mg, 64%), mp 176-179 °C, Rf = 0.27 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.86 (s, 3H, 18-
CH3), 0.93-0.96 (overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.07-1.15 (overlapping m, 3H), 1.46
(t, 3H, J = 7.0 Hz, OEt-CH3), 1.49-1.59 (overlapping m, 5H), 1.72 (m, 1H), 1.82-1.86 (overlapping m,
3H), 1.96 (m, 1H), 2.23-2.30 (overlapping m, 2H), 2.86 (m, 1H, 16-H), 3.51 (m, 1H, 3-H), 3.85 (dd,
1H, J = 9.0 Hz, J = 3.0 Hz, 17-H), 4.53 (q, 2H, J = 7.0 Hz, OEt-CH2), 4.67 (dd, 1H, J = 13.5 Hz,
J = 8.0 Hz, 16a-H), 5.04 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H), 5.32 (d, 1H, J = 3.5 Hz, 6-H);
ESI-MS: 445 (M+H)+; Anal. Calcd for C24H36N4O4: C, 64.84; H, 8.16; N, 12.60. Found: C, 64.97; H,
8.36; N, 12.84.
16β-(5-Benzyloxycarbonyl-1H-tetrazol-1-ylmethyl)androst-5-ene-3β,17β-diol (11c): Nitrile: benzyl
cyanoformate (8c, 0.16 mL) was added to the mixture. After purification, 11c was obtained as a white
1
solid (268 mg, 53%), mp 178-181 °C, Rf = 0.38 (ss B); H-NMR (CDCl3); δ [ppm] = 0.79 (s, 3H,
18-CH3), 0.87-0.94 (overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.05-1.15 (overlapping m, 3H), 1.42-
1.55 (overlapping m, 5H), 1.67 (m, 1H), 1.78-1.85 (overlapping m, 3H), 1.91 (m, 1H), 2.24-2.32

Molecules 2011, 16
4803
(overlapping m, 2H), 2.80 (m, 1H, 16-H), 3.51 (m, 1H, 3-H), 3.76 (dd, 1H, J = 9.5 Hz, J = 3.0 Hz,
17-H), 4.63 (dd, 1H, J = 13.5 Hz, J = 8.0 Hz, 16a-H), 5.01 (dd, 1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H),
5.32 (d, 1H, J = 4.0 Hz, 6-H), 5.47 (q, 2H, J = 12.0 Hz, OCH2Ph), 7.38 (m, 3H, 3”-, 4”- and 5”-H),
7.48 (d, 2H, J = 6.5 Hz, 2”- and 6”-H); ESI-MS: 507 (M+H)+; Anal. Calcd for C29H38N4O4: C, 68.75;
H, 7.56; N, 11.06. Found: C, 68.88; H, 7.74; N, 10.89.
16β-(5-Acetyl-1H-tetrazol-1-ylmethyl)androst-5-ene-3β,17β-diol (11d): Nitrile: acetyl cyanide (8d,
0.08 mL) was added to the mixture. After purification, 11d was obtained as a white solid (195 mg,
47%), mp 199-202 °C, Rf = 0.41 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.84 (s, 3H, 18-CH3), 0.93-0.97
(overlapping m, 2H), 1.02 (s, 3H, 19-CH3), 1.08-1.16 (overlapping m, 3H), 1.47-1.58 (overlapping m,
5H), 1.74 (m, 1H), 1.82-1.87 (overlapping m, 3H), 1.96 (m, 1H), 2.26-2.32 (overlapping m, 2H), 2.55
(s, 3H, 5’Ac-CH3), 2.86 (m, 1H, 16-H), 3.51 (m, 1H, 3-H), 3.83 (d, 1H, J = 9.5 Hz, 17-H), 4.66 (dd,
1H, J = 13.5 Hz, J = 7.5 Hz, 16a-H), 5.03 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.32 (d, 1H, J =
3.5 Hz, 6-H); ESI-MS: 415 (M+H)+; Anal. Calcd for C23H34N4O3: C, 66.64; H, 8.27; N, 13.52. Found:
C, 66.48; H, 8.38; N, 13.74.
16β-(5-Benzoyl-1H-tetrazol-1-ylmethyl)androst-5-ene-3β,17β-diol (11e): Nitrile: benzoyl cyanide (8e,
145 mg) was added to the mixture. After purification, 11e was obtained as a white solid (215 mg,
45%), mp 196-200 °C, Rf = 0.34 (ss B); 1H-NMR (CDCl3); δ [ppm] = 0.83 (s, 3H, 18-CH3), 0.91-0.96
(overlapping m, 2H), 1.03 (s, 3H, 19-CH3), 1.07-1.14 (overlapping m, 3H), 1.46-1.57 (overlapping m,
5H), 1.71 (m, 1H), 1.81-1.86 (overlapping m, 3H), 1.94 (m, 1H), 2.23-2.31 (overlapping m, 2H), 2.87
(m, 1H, 16-H), 3.51 (m, 1H, 3-H), 3.84 (d, 1H, J = 9.5 Hz, 17-H), 4.66 (dd, 1H, J = 13.5 Hz,
J = 7.5 Hz, 16a-H), 5.03 (dd, 1H, J = 13.5 Hz, J = 7.0 Hz, 16a-H), 5.32 (d, 1H, J = 4.0 Hz, 6-H), 7.56
(t, 2H, J = 7.5 Hz, 3”- and 5”-H), 7.70 (t, 1H, J = 7.5 Hz, 4”-H), 8.34 (d, 2H, J = 7.5 Hz, 2”- and
6”-H); ESI-MS: 477 (M+H)+; Anal. Calcd for C28H36N4O3: C, 70.56; H, 7.61; N, 11.76. Found: C,
70.77; H, 7.45; N, 11.89.
3.11. Determination of Antiproliferative Activities
Human cancer cell lines were purchased from ECACC (Salisbury, UK). HeLa (cervix
adenocarcinoma), A2780 (ovarian carcinoma) and MCF7 (breast adenocarcinoma) cells were
cultivated in minimal essential medium supplemented with 10% fetal bovine serum, 1% non-essential
amino acids and an antibiotic-antimycotic mixture.
Near-confluent cancer cells were seeded onto a 96-well microplate (5000/well) and attached to the
bottom of the well overnight. On the second day, new medium containing the tested compound (at
10 or 30 µM, 200 μL) was added. After incubation for 72 h at 37 °C in humidified air containing 5%
CO2, the living cells were assayed by the addition of 5 mg/mL MTT solution (20 μL). MTT was
converted by intact mitochondrial reductase and precipitated as blue crystals during a 4 h contact
period. The medium was then removed and the precipitated crystals were dissolved in 100 μL DMSO
during a 60 min period of shaking at 25 °C. Finally, the reduced MTT was assayed at 545 nm, using a
microplate reader; wells with untreated cells were utilized as controls [31]. All in vitro experiments
were carried out on two microplates with at least five parallel wells. Cisplatin was used as positive

Molecules 2011, 16
4804
control. Stock solutions of the tested substances (10 mM) were prepared with DMSO. The DMSO
content of the medium (0.1% or 0.3%) did not have any significant effect on the cell proliferation.
4. Conclusions
In summary, the efficient syntheses of several D-ring-substituted steroidal triazoles and tetrazoles
were achieved by means of 1,3-dipolar cycloadditions. The simple and fast reactions were carried out
under mild conditions that furnished the desired compounds in good yields. The novel synthesized
compounds were screened for their activities against a panel of three human gynecological cancer cell
lines (HeLa, MCF7 and A2780). The application of “click” chemistry to further sterane skeletons was
encouraged by these promising results.
Acknowledgments
This work was supported by the New Hungary Development Plan (TÁMOP 4.2.1/B-09/1/KONV-
2010-0005) and the Hungarian Scientific Research Fund (OTKA PD72403 and K101659). The
project named “TÁMOP-4.2.1/B-09/1/KONV-2010-0005 – Creating the Center of Excellence at the
University of Szeged” is supported by the European Union and co-financed by the European
Regional Fund.
Conflict of Interest
The authors declare no conflict of interest.
References and Notes
1. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise Huisgen cycloaddition
process: Copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew.
Chem., Int. Ed. 2002, 41, 2596-2599.
2. Tornøe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by
regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org.
Chem. 2002, 67, 3057-3064.
3. Bock, V.D.; Hiemstra, H.; Van Maarseveen, J.H. CuI-catalyzed alkyne-azide “click”
cycloadditions from a mechanistic and synthetic perspective. Eur. J. Org. Chem. 2006, 1, 51-68.
4. Wu, P.; Fokin, V.V. Catalytic azide-alkyne cycloaddition: Reactivity and applications. Aldrichim.
Acta 2007, 40, 7-17.
5. Hein, C.D.; Liu, X.M.; Wang, D. Click chemistry, a powerful tool for pharmaceutical sciences.
Pharm. Res. 2008, 25, 2216-2230.
6. Klaubert, D.H.; Sellstedt, J.H.; Guinosso, C.J.; Bell, S.C.; Capetola, R.J. 5-Tetrazolecarboxamides
and their salts: new orally active antiallergy agents. J. Med. Chem. 1981, 24, 748-752.
7. Demko, Z.P.; Sharpless, K.B. A click chemistry approach to tetrazoles by Huisgen 1,3-dipolar
cycloaddition: Synthesis of 5-acyltetrazoles from azides and acyl cyanides. Angew. Chem., Int.
Ed. 2002, 41, 2113-2116.

Molecules 2011, 16
4805
8. Demko, Z.P.; Sharpless, K.B. A click chemistry approach to tetrazoles by Huisgen 1,3-dipolar
cycloaddition: Synthesis of 5-sulfonyl tetrazoles from azides and sulfonyl cyanides. Angew.
Chem., Int. Ed. 2002, 41, 2110-2113.
9. Bosch, L.; Vilarrasa, J. Cu2(OTf)2-catalyzed and microwave-controlled preparation of tetrazoles
from nitriles and organic azides under mild, safe conditions. Angew. Chem., Int. Ed. 2007, 46,
3926-3930.
10. Salomon, R.G.; Kochi, J.K. Copper(I) catalysis in cyclopropanations with diazo compounds. The
role of olefin coordination. J. Am. Chem. Soc. 1973, 95, 3300-3310.
11. Pore, V.S.; Aher, N.G.; Kumar, M.; Shukla, P.K. Design and synthesis of fluconazole/bile acid
conjugate using click reaction. Tetrahedron 2006, 62, 11178-11186.
12. Aher, N.G.; Pore, V.S.; Patil, S.P. Design, synthesis, and micellar properties of bile acid dimers
and oligomers linked with a 1,2,3-triazole ring. Tetrahedron 2007, 63, 12927-12934.
13. Aher, N.G.; Pore, V.S. Synthesis of bile acid dimers linked with 1,2,3-triazole ring at C-3, C-11,
and C-24 positions. Synlett 2005, 14, 2155-2158.
14. Zhang, Z.; Ju, Y.; Zhao, Y. Synthesis of 1,2,3-triazole-containing bile acid dimers and properties
of inverse micellar mimic. Chem. Lett. 2007, 36, 1450-1452.
15. Banday, A.H.; Shameem, S.A.; Gupta, B.D.; Sampath-Kumar, H.M. D-ring substituted 1,2,3-
triazolyl 20-keto pregnenanes as potential anticancer agents: Synthesis and biological evaluation.
Steroids 2010, 75, 801-804.
16. Iványi, Z.; Wölfling, J.; Görbe, T.; Szécsi, M.; Wittmann, T.; Schneider, G. Synthesis of
regioisomeric 17β-N-phenylpyrazolyl steroid derivatives and their inhibitory effect on 17α-
hydroxylase/C17,20-lyase. Steroids 2010, 75, 450-456.
17. Ondré, D.; Wölfling, J.; Tóth, I.; Szécsi, M.; Julesz, J.; Schneider, G. Steroselective synthesis of
some steroidal oxazolines, as novel potential inhibitors of 17α-hydroxylase-C17,20-lyase. Steroids
2009, 74, 1025-1032.
18. Ondré, D.; Wölfling, J.; Iványi, Z.; Schneider, G.; Tóth, I.; Szécsi, M.; Julesz, J. Neighboring
group participation: Part 17 Stereoselective synthesis of some steroidal 2-oxazolidones, as novel
potential inhibitors of 17α-hydroxylase-C17,20-lyase. Steroids 2008, 73, 1375-1384.
19. Frank, É.; Mucsi, Z.; Zupkó, I.; Réthy, B.; Falkay, G.; Schneider, G.; Wölfling, J. Efficient
approach to androstene-fused arylpyrazolines as potent antiproliferative agents. Experimental and
theoretical studies of substituent effects on BF3-catalyzed intramolecular [3+2] cycloadditions of
olefinic phenylhydrazones. J. Am. Chem. Soc. 2009, 131, 3894-3904.
20. Genin, M.J.; Allwine, D.A.; Anderson, D.J.; Barbachyn, M.R.; Emmert, D.E.; Garmon, S.A.;
Graber, D.R.; Grega, K.C.; Hester, J.B.; Hutchinson, D.K.; et al. Substituent effects on the
antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded
activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella
catarrhalis. J. Med. Chem. 2000, 43, 953-970.
21. Alvarez, R.; Velazquez, S.; San-Felix, A.; Aquaro, S.; De Clercq, E.; Perno, C.F.; Karlsson, A.;
Balzarini, J.; Camarasa, M.J. 1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-
ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis
and anti-HIV-1 activity. J. Med. Chem. 1994, 37, 4185-4194.

Molecules 2011, 16
4806
22. Buckle, D.R.; Rockell, C.J.; Smith, H.; Spicer, B.A. Piperazinylalkoxy-[1]benzopyrano[2,3-d]-
1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
J. Med. Chem. 1986, 29, 2262-2267.
23. Palhagen, S.; Canger, R.; Henriksen, O.; van Parys, J.A.; Riviere, M.E.; Karolchyk, M.A.
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.
Epilepsy Res. 2001, 43, 115-124.
24. Reddy, D.M.; Srinivas, J.; Chashoo, G.; Saxena, A.K.; Kumar, H.M.S. 4β-[(4-Alkyl)-1,2,3-triazol-
1-yl] podophyllotoxins as anticancer compounds: Design, synthesis and biological evaluation.
Eur. J. Med. Chem. 2011, 46, 1983-1991.
25. Fu, J.; Yang, Y.; Zhang, X.W.; Mao, W.J.; Zhang, Z.M.; Zhu, H.L. Discovery of 1H-
benzo[d][1,2,3]triazol-1-yl-3,4,5-trimethoxybenzoate as a potential antiproliferative agent by
inhibiting histone deacetylase. Bioorg. Med. Chem. 2010, 18, 8457-8462.
26. Gundugola, A.S.; Chandra, K.L.; Perchellet, E.M.; Waters, A.M.; Perchellet, J.P.H.; Rayat, S.
Synthesis and antiproliferative evaluation of 5-oxo and 5-thio derivatives of 1,4-diaryl tetrazoles.
Bioorg. Med. Chem. Lett. 2010, 20, 3920-3924.
27. Ruzička, L.; Prelog, V.; Battegay, J. Steroide und sexualhormone. 153. Mitteilung. Über einige
Benzo-perhydro-cyclopenteno-phenanthren-derivate. Helv. Chim. Acta 1948, 31, 1296-1301.
28. Schneider, G.; Vincze, I.; Vass, A. Steroids, XIX. Neighbouring group participation, III. (AcO-6)
and (PrO-6) neighbouring group participation in the 16-hydroxymethylandrost-5-ene-3,17-diol
series. Acta Chim. Acad. Sci. Hung. 1979, 99, 51-67.
29. Meldal, M.; Tornøe, C.W. Cu-catalyzed azide-alkyne cycloaddition. Chem. Rev. 2008, 108,
2952-3015.
30. Lee, B.Y.; Park, S.R.; Jeon, H.B.; Kim, K.S. A new solvent system for efficient synthesis of 1,2,3-
triazoles. Tetrahedron Lett. 2006, 47, 5105-5109.
31. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to
proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
Sample Availability: Samples of the compounds 5, 6a-j, 7a-j, 9a-e, 10 and 11a-e are available from
the authors.
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).